장기지속형 항정신병약물의 임상 실제

참고문헌 (62)

1. Agid O, "Long-acting injectable antipsychotics in the treatment of schizophrenia : their role in relapse prevention", Expert Opin Pharmacother, 11, pp.2301~2317 (2010)
2. Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
3. Johnson DA, "Historical perspective on antipsychotic long-acting injections", Br J Psychiatry Suppl, 52, pp.S7~S12 (2009)
4. Naber D, "The CATIE and CUtLASS studies in schizophrenia", CNS Drugs, 23, pp.649~659 (2009)
5. Tiihonen J, "A nationwide chohort study of oral and depot antipsychotics after first hospitalization for schizophrenia", Am J Psychiatry, 168, pp.603~609 (2011)
6. Kane JM, "Long-acting injectable risperidone : efficacy and safety of the first long acting atypical antipsychotic", Am J Psychiatry, 160, pp.1125~1132 (2003)
7. Fleischhacker WW, "Treatment of schizophrenia with longacting injectable risperidone : a 12-month open-label trial of the first long-acting second-generation antipsychotic", J Clin Psychiatry, 64, pp.1250~1257 (2003)
8. Chue P, "Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets", Eur Neuropsychopharmacol, 15, pp.111~117 (2005)
9. Rosenheck RA, "Long-acting risperidone and oral antipsychotics in unstable schizophrenia", N Engl J Med, 364, pp.842~851 (2011)
10. Rauch AS, "Long-acting injectable formulations of new-generation antipsychotics : a review from a clinical perspective", CNS Drugs, 27, pp.637~652 (2013)
11. Bushe CJ, "Olanzapine long-acting injection : a review of first experiences of post-injection delirium", sedation syndrome in routine clinical practice, 2015, pp.15, 65~
12. Alphs L, "Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics", Neuropsychiatr Dis Treat, 9, pp.341~350 (2013)
13. Fu DJ, "Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects : onset of efficacy with recommended initiation regimens", Clin Schizophr Relat Psychoses, 8, pp.101~109 (2014)
14. Fu DJ, "Paliperidone palmitate versus oral risperidone and risperidone longacting injection in patients with recently diagnosed schizophrenia : a tolerability and efficacy comparison", Int Clin Psychopharmacol, 29, pp.45~55 (2014)
15. Berwaerts J, "Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia : a randomized clinical trial", JAMA Psychiatry, 72, pp.830~839 (2015)
16. Savitz AJ, "Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study", Int J Neuropsychopharmacol, 19, pp.pyw018~ (2016)
17. Kane JM, "Aripirazole intramuscular depot as maintenance treatment in patients with schizophrenia : a 52-week, multicenter, randomized, doubleblind, placebo-controlled study", J Clin Psychiatry, 73, pp.617~624 (2012)
18. Fleischhacker WW, "Aripiprazole oncemonthly for treatment of schizophrenia : double-blind, randomised, non-inferiority study", Br J Psychiatry, 205, pp.135~144 (2014)
19. Ishigooka J, "Efficacy and safety of aripiprazole oncemonthly in Asian patients with schizophrenia : a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole", Schizophr Res, 161, pp.421~428 (2015)
20. Naber D, "Qualify : a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia", Schizophr Res, 168, pp.498~504 (2015)
21. Aggarwal A, "Aripiprazole lauroxil longacting injectable : the latest addition to second-generation long-acting agents", Clin Schizophr Relat Psychoses, 10, pp.58~63 (2016)
22. Meltzer HY, "A randomized, doubleblind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia", J Clin Psychiatry, 76, pp.1085~1090 (2015)
23. Correll CU, "The use of long-acting injectable antipsychotics in schizophrenia:evaluating the evidence", J Clin Psychiatry, 77(suppl 3), pp.1~24 (2016)
24. Kishimoto T, "Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia : a meta-analysis of randomized trials", Schizophr Bull, 40, pp.192~213 (2014)
25. Ostuzzi G, "Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies", Schizophr Res, 183, pp.10~21 (2017)
26. Kishimoto T, "Longacting injectable versus oral antipsychotics in schizophrenia : a systematic review and meta-analysis of mirror-image studies", J Clin Psychiatry, 74, pp.957~965 (2013)
27. Haddad PM, "The place of observational studies in assessing the effectiveness of depot antipsychotics", Schizophr Res, 131, pp.260~261 (2011)
28. Brissos S, "The role of longacting injectable antipsychotics in schizophrenia : a critical appraisal", Ther Adv Psychopharmacol, 4, pp.198~219 (2014)
29. Zhornitsky S, "Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence : a systematic review", Schizophr Res Treat, 2012, pp.407171~ (2012)
30. Iyer S, "A qualitative study of experiences with and perceptions regarding longacting injectable antipsychotics: part I-patient perspectives", Can J Psychiatry, 58(5 Suppl 1), pp.14S~22S (2013)
31. Subotnik KL, "Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial", JAMA Psychiatry, 72, pp.822~829 (2015)
32. Schreiner A, "Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia", Schizophr Res, 169, pp.393~399 (2015)
33. Gentile S, "Adverse effects associated with second-generation antipsychotic long-acting injection treatment : a comprehensive systematic review", Pharmacotherapy, 33, pp.1087~1106 (2013)
34. Hamer J, "One-year treatment continuation in patients switched to paliperidone palmitate : a retrospective study", J Clin Psychiatry, 75, pp.1267~1269 (2014)
35. Malla A, "Long-acting injectable antipsychotics: recommendations for clinicians", Can J Psychiatry, 58(5 Suppl 1), pp.30S~35S (2013)
36. Leucht S, "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis", Lancet, 382, pp.951~962 (2013)
37. Misawa F, "Safety and tolerability of long-acting injectable versus oral antipsychotics : a metaanalysis of randomized controlled studies comparing the same antipsychotics", Schizophr Res, 176, pp.220~230 (2016)
38. Uchida H, "Dose and dosing frequency of long-acting injectable antipsychotics : a systematic review of PET and SPECT data and clinical implications", J Clin Psychopharmacol, 34, pp.728~735 (2014)
39. Seeman P, "Schizophrenia and the supersensitive synapse", Neuropsychiatry, 1, pp.233~242 (2011)
40. Kimura H, "A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis", Schizophr Res, 155, pp.52~58 (2014)
41. Muller P, "Presynaptic subsensitivity as a possible basis for sensitization by long-term dopamine mimetics", Eur J Pharmacol, 55, pp.149~157 (1979)
42. Sreeraj VS, "A critical appraisal of long acting injectable antipsychotics : translating research to clinics", Asian J Psychiatr, 28, pp.57~64 (2017)
43. Morrissette DA, "Optimizing outcomes in schizophrenia : longacting depots and long-term treatment", CNS Spectr, 17, pp.10~21 (2012)
44. Patel MX, "Antipsychotic long-acting injections : mind the gap", Br J Psychiatry Suppl, 52, pp.S1~S4 (2009)
45. Valenstein M, "Poor antipsychotic adherence among patients with schizophrenia : medication and patient factors", Schizophr Bull, 30, pp.255~264 (2004)
46. De Hert M, "The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia : a systematic review and meta-analysis of randomized controlled trials with first-and second-generation antipsychotics", CNS Drugs, 29, pp.637~658 (2015)
47. Ho BC, "Long-term antipsychotic treatment and brain volumes : a longitudinal study of first episode schizophrenia", Arch Gen Psychiatry, 68, pp.128~137 (2011)
48. Haijma SV, "Brain volumes in schizophrenia : a meta-analysis in over 18 000 subjects", Schizophr Bull, 39, pp.1129~1138 (2013)
49. Bartzokis G, "Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia", Schizophr Res, 140, pp.122~128 (2012)
50. Heres S, "Psychiatrists’ attitudeto antipsychotic depot treatment in patients with first-episode schizophrenia", Eur Psychiatry, 26, pp.297~301 (2011)
51. Patel MX, "Psychiatrists’ attitudes to maintenance medicationfor patients with schizophrenia", Psychol Med, 33, pp.83~89 (2003)
52. Patel MX, "Antipsychotic depot medicationand attitudes of community psychiatric nurses", J Psychiatr Ment Health Nurs, 12, pp.237~244 (2005)
53. Iyer S, "A qualitative study of experiences with and perceptions regarding longacting injectable antipsychotics: part II-physician perspectives", Can J Psychiatry, 58(5 Suppl 1), pp.23S~29S (2013)
54. Hamann J, "How much more effective do depotantipsychotics have to be compared to oral antipsychotics before they are prescribed", Eur Neuropsychopharmacol, 20, pp.276~279 (2010)
55. Heres S, "Attitudes of psychiatrists toward antipsychotic depot medication", J Clin Psychiatry, 67, pp.1948~1953 (2006)
56. Patel MX, "Psychiatrists’ use, knowledge and attitudesto first-and second-generation antipsychotic long-acting injections : comparisons over 5 years", J Psychopharmacol, 24, pp.1473~1482 (2010)
57. Weiden PJ, "The challenge of offering long-acting antipsychotic therapies : a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia", J Clin Psychiatry, 76, pp.684~690 (2015)
58. Carpenter WT Jr, "Expanding therapy with long-acting antipsychotic medication in patients with schizophrenia", JAMA Psychiatry, 72, pp.745~746 (2015)
59. Salgueiro M, "Long-acting injectable second-generation antipsychotics in first-episode psychosis : a narrative review", Int Clin Psychopharmacol, 34, pp.51~56 (2019)
60. Agid O, "Antipsychotic response in first-episode schizophrenia : efficacy of high doses and switching", Eur Neuropsychopharmacol, 23, pp.1017~1022 (2013)
61. Suzuki T, "A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia : a narrative review and critical appraisal", Expert Opin Drug Deliv, 13, pp.253~264 (2016)
62. Bruijnzeel D, "Antipsychotic treatment of schizophrenia : an update", Asian J Psychiatry, 11, pp.3~7 (2014)

관련 논문AI추천